Principal CADD Scientist

Menlo Ventures; San Diego (CA); On-site; USD 120,000 - 180,000; Full time

Job summary

A leading biotechnology company in San Diego is seeking a Principal CADD Scientist to drive drug discovery through advanced computational chemistry techniques. The role involves utilizing AI tools, collaborating with a talented team, and contributing to innovative drug discovery initiatives targeting complex conditions.

Benefits

Competitive Pay

Health Care Plans fully covered

Stock Option Eligibility

401(k) Plan

Open PTO Policy

Paid Company Holidays

Free lunch and snacks

Qualifications

• Deep understanding of structure-based drug design.
• Minimum of 5+ years as a CADD scientist in drug discovery.
• Collaboration skills crucial for cross-team communication.

Responsibilities

• Utilize AI-powered CADD tools in drug discovery.
• Collaborate with medicinal chemists on molecular design.
• Adapt to innovative and fast-paced work environment.

Skills

Structure-based drug design

Protein-ligand interactions

CADD tools

Education

PhD in Computational Chemistry or related field

PhD in organic or medicinal chemistry

Tools

MOE

PyMOL

Schrodinger Suite

Job description

Genesis Therapeutics is assembling a world-class computational chemistry team to revolutionize drug discovery through cutting-edge machine learning and biophysical simulation. We are seeking a Principal CADD Scientist to join our on-site discovery team in San Diego, working directly with scientists in our state-of-the-art wet lab and with our distributed computational chemistry and CADD science teams across the US.

What You Will Do (Key Responsibilities)

• Utilize a combination of industry-standard and proprietary AI-powered CADD tools to guide small molecule drug discovery programs across a diverse target portfolio, including novel targets with limited chemical precedents.
• Use approaches like virtual screening, molecular simulation, and potency and ADMET prediction to support key decision-making in drug discovery efforts.
• Collaborate closely with medicinal chemists in molecular design and the development of project-specific computational approaches.
• Act as a cross-team connector, effectively communicating between our computational chemistry and medicinal chemistry teams to ensure seamless information flow and collaborative decision making.
• Adapt to a fast-paced environment where innovation and quick iteration are encouraged.

What you’ll bring

• PhD in Computational Chemistry, Structural Biology, or a related field. This particular role may also be suitable for PhD-level scientists with degrees in organic or medicinal chemistry with extensive experience in the lab, who have transitioned into industry roles in CADD.
• Deep understanding of structure-based drug design and protein-ligand interactions.
• Proficiency with industry-standard CADD tools such as MOE, PyMOL, and Schrodinger Suite.
• Minimum of 5+ years of industry experience as a CADD scientist in pharma or biotech, with hands-on experience in active drug discovery programs.

What we offer

• Competitive Pay
• Health Care Plans (including Medical, Dental, and Vision, fully covered for the employees)
• Stock Option Eligibility
• 401(k) Plan
• Open PTO Policy
• Paid Company Holidays
• Free lunch and snacks at our offices

Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules.

Our team has created the industry's most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets.

The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has signed AI-focused platform collaborations with major pharmaceutical companies, including most recently Incyte Corporation (Feb 2025) and Gilead Sciences (Sept 2024).

We raised a $200M series B in August 2023, and have raised over $300M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures.

Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.